Flag of the European Union EU Clinical Trials Register Help

Clinical trials for roche OR chugai OR genentech

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,190 result(s) found for: roche OR chugai OR genentech. Displaying page 150 of 160.
    «« First « Previous 146  147  148  149  150  151  152  153  154  Next» Last»»
    EudraCT Number: 2012-003633-42 Sponsor Protocol Number: RBHIPF004 Start Date*: 2013-10-18
    Sponsor Name:Royal Brompton and Harefield NHS Foundation Trust
    Full Title: A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease
    Medical condition: A diagnosis of connective tissue disease associated interstitial lung disease, based on internationally accepted criteria, in one of the following categories: o Systemic sclerosis o Idiopathic inte...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10022611 Interstitial lung disease PT
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10027754 Mixed connective tissue disease PT
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039710 Scleroderma PT
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10036102 Polymyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-006755-44 Sponsor Protocol Number: 2008-510 Start Date*: 2009-01-15
    Sponsor Name:HOSPICES CIVILS DE LYON
    Full Title: METAFORE : Maladie de Rendu-Osler : Etude de l’Efficacité et de la tolérance du Bevacizumab utilisé pour le traitement des formes hépatiques sévères. Etude de phase II
    Medical condition: Maladie de Rendu-Osler
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031132 Osler-Weber-Rendu disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001682-33 Sponsor Protocol Number: 6176/RADS2 Start Date*: 2012-09-06
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: Combined Immunotherapy and Trophic Adrenocortical Stimulation in New Onset Autoimmune Addison’s Disease
    Medical condition: Autoimmune Addison's disease: autoimmune primary adrenal insufficiency
    Disease: Version SOC Term Classification Code Term Level
    16.1 10014698 - Endocrine disorders 10052381 Primary adrenal insufficiency PT
    16.1 10014698 - Endocrine disorders 10001335 Adrenal cortex insufficiency LLT
    16.1 10014698 - Endocrine disorders 10001342 Adrenal cortical hypofunction LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-001549-42 Sponsor Protocol Number: STH19379 Start Date*: 2020-03-27
    Sponsor Name:Sheffield Teaching Hospitals
    Full Title: A multicentre, randomised controlled trial to evaluate the efficacy of autologous haematopoietic stem cell transplantation versus alemtuzumab or ocrelizumab in relapsing remitting multiple sclerosis.
    Medical condition: Highly active relapsing remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-001553-12 Sponsor Protocol Number: 2SMALL Start Date*: 2019-11-28
    Sponsor Name:Fundacion ONCOSUR
    Full Title: Phase I-II Study to Assess the Safety, Tolerability and Efficacy of PM01183 and Atezolizumab in Patients with Advanced Small Cell Lung Cancer that Progressed Following Prior Therapy with Platinum-B...
    Medical condition: Histologically or cytologically confirmed diagnosis of extensive or limited SCLC. Progression to first-line platinum-based chemotherapy. Measurable disease according to RECIST v.1.1.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001591-80 Sponsor Protocol Number: INFL08 Start Date*: 2008-05-12
    Sponsor Name:G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI
    Full Title: PHASE II STUDY OF LENALIDOMIDE IN COMBINATION WITH RITUXIMAB (R) FOR THE TREATMENT OF INDOLENT NON FOLLICULAR NON HODGKIN LYMPHOMA
    Medical condition: Histological proved diagnosis of B-cell CD20-positive non follicular NHL according to REAL/WHO Classification: a. small lymphocytic lymphoma b. lymphoplasmacytic lymphoma/Waldenstrom macroglobul...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029463 LLT
    9.1 10003911 LLT
    9.1 10041652 LLT
    9.1 10025345 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000544-86 Sponsor Protocol Number: 11848 Start Date*: Information not available in EudraCT
    Sponsor Name:Bayer HealthCare AG; D-51368 Leverkusen
    Full Title: A randomised, open-label, multi-center phase II study of first-line treatment with BAY 43-9006 (Sorafenib) versus standard treatment with Interferon alpha-2a in patients with unresectable and/or me...
    Medical condition: unresectable and/or metastatic renal cell carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-019500-23 Sponsor Protocol Number: MPD-RC111 Start Date*: 2012-02-15
    Sponsor Name:CONSORZIO MARIO NEGRI SUD
    Full Title: Single Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High Risk Polycythemia Vera or High Risk Essential Thrombocythemia who are Either Hydroxyurea Resistant or Intolerant ...
    Medical condition: High risk polycythemia vera and high risk essential thrombocythemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036057 Polycythaemia vera PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015493 Essential thrombocythaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001207-42 Sponsor Protocol Number: CONFERMER Start Date*: 2014-06-03
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI PARMA
    Full Title: Multicenter randomized trial comparing erlotinib vs mono-chemotherapy in the third-line treatment of non-small cell lung cancer (NSCLC) patients with EGFR-mutated or unknown
    Medical condition: Third-line treatment in patients with non-small cell lung cancer (NSCLC) patients with EGFR-mutated or unknown
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-005388-34 Sponsor Protocol Number: SOF Start Date*: 2015-05-20
    Sponsor Name:AZIENDA OSPEDALIERA DI PADOVA
    Full Title: Single arm prospective clinical study to evaluate the efficacy of combination therapy sofosbuvir+ribavirin+peg-interferon in experienced patients with HCV-GT1
    Medical condition: chronic hepatitis HCV GT1 who have already failed a prior course of dual therapy with pegylated interferon + ribavirin
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10057212 Hepatitis viral infections HLT
    19.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020033-14 Sponsor Protocol Number: CDEB025A2210 Start Date*: 2010-09-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicentre, randomized, double-blind, placebocontrolled, parallel-group phase II study on efficacy and safety of DEB025 combined with peg-IFN alfa-2a and ribavirin in chronic hepatitis C genotyp...
    Medical condition: Chronic Hepatitis C Genotype 1 patients
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) DE (Completed) FR (Completed) ES (Completed) BE (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-005083-28 Sponsor Protocol Number: BAY 43-9006 / 12782 Start Date*: 2008-02-27
    Sponsor Name:Bayer Healthcare AG, Leverkusen
    Full Title: Estudio de fase II, aleatorizado, abierto, multicéntrico, para evaluar la eficacia de sorafenib solo y sorafenib en combinación con interferón alfa-2a a dosis bajas como tratamiento de segunda líne...
    Medical condition: Carcinoma metastásico de células renales (Advanced renal cell cancer.)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038407 Renal cell cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) GB (Prematurely Ended) FR (Completed) IT (Prematurely Ended) IE (Prematurely Ended) AT (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001335-36 Sponsor Protocol Number: 2007.495/38 Start Date*: 2008-05-15
    Sponsor Name:HOSPICES CIVILS DE LYON
    Full Title: Evaluation de la fonction rénale après introduction de l’évérolimus chez le transplanté cardiaque présentant une insuffisance rénale chronique : étude multicentrique, randomisée en ouvert
    Medical condition: Transplanté cardiaque présentant une insuffisance rénale chronique
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007611 Cardiac transplant LLT
    9.1 10009119 Chronic renal failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002563-25 Sponsor Protocol Number: VEGF-RTX-2013 Start Date*: 2014-01-13
    Sponsor Name:VU University Medical Centre
    Full Title: Pilot study to determine the effect of fractionated radiotherapy on expression of pro-angiogenic factors in oeshophagus carcinoma
    Medical condition: Angiogenesis in esophageal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10015362 Esophageal cancer LLT
    20.0 100000004864 10030151 Oesophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003912-72 Sponsor Protocol Number: H3E-MC-S103a Start Date*: 2007-10-31
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Randomized Phase 2 Study Comparing Erlotinib-Pemetrexed, Pemetrexed alone, and Erlotinib alone, as Second-Line Treatment for Non-Smoker Patients with Locally Advanced or Metastatic Non-Small Cell...
    Medical condition: Patients with histological or cytological diagnosis of nonsquamous NSCLC with locally advanced or metastatic disease. Patients must have failed only one prior chemotherapy regimen and must be consi...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029520 Non-small cell lung cancer stage IIIA LLT
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004097-41 Sponsor Protocol Number: 2008.512/13 Start Date*: 2008-08-21
    Sponsor Name:Hospices Civils de Lyon
    Full Title: « OCTO : Quantification de l’impact des variations d’Observance d’une ChimioThérapie Orale par l’utilisation de piluliers électroniques et modélisation des marqueurs de toxicités»
    Medical condition: Breast cancer female Colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057654 Breast cancer female LLT
    9.1 10061451 Colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000550-75 Sponsor Protocol Number: RG_05-004 Start Date*: 2006-02-24
    Sponsor Name:University of Birmingham
    Full Title: Phase II Study of the Tolerability and Efficacy of the Histone Deacetylase Inhibitor Sodium Valproate given in Conjunction with 5-azacytidine and ATRA (all trans retinoic acid ) in Patients with Ac...
    Medical condition: Patients who have Acute Myeloid Leukaemia (AML) or Myelodysplasia (MDS) will be recruited to this trial
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028532 Myelodysplasia LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004442-15 Sponsor Protocol Number: HISTORY Start Date*: 2013-09-11
    Sponsor Name:University Leipzig
    Full Title: High-dose intravenous silibinin infusions during 10 days as add-on treatment to triple therapy (telaprevir, peginterferon alpha and ribavirin) in cirrhotic GT 1 hepatitis C virus infected patients ...
    Medical condition: High-dose intravenous silibinin infusions during 10 days as add-on treatment to triple therapy (telaprevir, peginterferon alpha and ribavirin) in cirrhotic GT 1 hepatitis C virus infected patients ...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004871 10019642 Hepatic cirrhosis NOS LLT
    16.1 100000004848 10072848 Hepatitis C virus genotype 1 positive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023880-17 Sponsor Protocol Number: RR10/9589 Start Date*: 2011-03-31
    Sponsor Name:University of Leeds
    Full Title: SWITCH: Randomised-controlled trial of switching to alternative tumour-necrosis factor (TNF)-blocking drugs or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initia...
    Medical condition: Rheumatoid arthritis in patients who have failed to respond to an initial TNF-blocking drug
    Disease: Version SOC Term Classification Code Term Level
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-020966-34 Sponsor Protocol Number: ICORG10-05 Start Date*: 2010-08-06
    Sponsor Name:ICORG
    Full Title: A phase II neoadjuvant study assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Traztuzumab and Lapatinib) in Erb B2 positive breast cancer patients
    Medical condition: Her 2 positive locally advanced or primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 146  147  148  149  150  151  152  153  154  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 05:32:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA